Test Price
2,800 AED✅ Home Collection Available
GLB1 Gene Mucopolysaccharidosis Type 4B Genetic Test in UAE
Executive Summary & Core Metrics
Service Overview: High-sensitivity GLB1 gene sequencing for Mucopolysaccharidosis IVB (Morquio syndrome B) using ISO-accredited next-generation sequencing (NGS) technology. This test provides definitive molecular diagnosis, carrier detection, and family planning guidance under UAE regulatory oversight.
- Accuracy: 99.9% diagnostic sensitivity for SNVs and small indels via NGS with orthogonal Sanger confirmation.
- Turnaround Time: 3–4 weeks from sample receipt.
- Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM–11 PM).
- Price: 2,800 AED (inclusive of pre- and post-test genetic counseling).
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The GLB1 gene encodes beta-galactosidase; pathogenic variants cause Mucopolysaccharidosis type IVB (Morquio syndrome B), a progressive lysosomal storage disorder affecting skeletal, cardiac, and respiratory systems. Our test employs full-gene NGS covering all coding exons and ±20 bp intronic flanking regions, with confirmatory Sanger sequencing for all reported variants. This approach detects single-nucleotide variants and small insertions/deletions with >99.9% accuracy, aligned with current DHA and MOHAP standards for molecular diagnostics.
| Feature | Our Test: GLB1 NGS | Closest Alternative: Targeted Sanger Sequencing |
|---|---|---|
| Coverage | Full gene (all exons, ±20bp intronic regions) | Limited to known hotspot regions |
| Method | NGS + orthogonal Sanger confirmation | Single‑direction Sanger only |
| Sensitivity | >99.9% for SNVs & small indels | ~85% depending on region coverage |
| Turnaround | 3–4 weeks | 4–6 weeks |
| Regulatory Alignment | DHA/MOHAP NGS standards | Legacy protocols, limited validation |
Physician Insight & Safety Protocols
"As a consultant medical geneticist, I emphasize that the GLB1 gene test is a powerful diagnostic tool but must never replace a comprehensive clinical evaluation. A positive result indicates a pathogenic variant linked to Morquio syndrome B, but its interpretation requires correlation with enzyme activity, skeletal imaging, and family history. Our team provides pre-and post-test counseling to ensure patients fully understand implications for treatment, surveillance, and reproductive planning. Always discuss results with a Board-certified genetic specialist before making any medical decisions." — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Important Clinical Note
Do not discontinue or modify any prescribed therapy—including enzyme replacement or supportive medications—based solely on genetic test results. Always consult your treating physician before making changes to your treatment regimen.
Safety Exclusion Criteria & Red Flags
- Exclusion: Asymptomatic minors under 18 years without confirmed family history and pre-test genetic counseling, per UAE Federal Decree-Law No. 2 of 2019 on health data use.
- Exclusion: Patients who have not completed a pre-test genetic counseling session including a three-generation pedigree.
- Red Flag: Progressive skeletal dysplasia, hearing loss, or cardiac valvular abnormalities require urgent evaluation by a metabolic specialist; do not rely solely on this test for clinical decisions.
- Red Flag: A positive result in a pregnant patient necessitates immediate referral to a clinical geneticist and maternal-fetal medicine team.
- Emergency: If the patient exhibits acute respiratory distress or spinal cord compression symptoms, proceed to the nearest emergency department immediately.
Patient FAQ & Clinical Guidance
1. What is the purpose of the GLB1 gene NGS test?
This test identifies pathogenic variants in the GLB1 gene to confirm or rule out Mucopolysaccharidosis type IVB (Morquio B). It is used for symptomatic patients with clinical suspicion, carrier testing in at-risk relatives, and prenatal diagnosis after thorough genetic counseling. NGS technology detects single nucleotide changes and small insertions/deletions with near-complete accuracy.
2. How accurate is the NGS test compared to older methods?
Our NGS test achieves diagnostic sensitivity exceeding 99.9% for GLB1 variants, validated by orthogonal Sanger sequencing. Unlike targeted single-gene Sanger tests that may miss deep intronic or novel variants, full-gene NGS with clinically driven bioinformatics minimizes false-negative risks and meets current DHA quality metrics.
3. What are the sample requirements and how long do results take?
A whole blood sample (3–5 mL in EDTA), extracted DNA, or a dried blood spot on an FTA card is accepted. Collection can be arranged at your home with our VIP Mobile Phlebotomy service daily from 8 AM to 11 PM. Turnaround time is 3–4 weeks, inclusive of comprehensive bioinformatic analysis and clinical report writing.
4. Is pre-test genetic counseling mandatory?
Yes, pre-test genetic counseling is required for all patients to ensure informed consent. Our genetic counselors explain the scope, limitations, possible results, and implications for family members. This session is included in the test price.
5. Will my insurance cover this test?
Direct billing verification is available via WhatsApp at +971 54 548 8731. Coverage varies by insurance plan; we recommend checking with your provider prior to testing.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This genetic test is performed under DHA Facility License No. 1143 and adheres to all applicable UAE federal laws, including:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – safeguarding patient genetic data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing digital health records and test reporting.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – ensuring clinical safety and patient consent.
All genetic information is handled with strict confidentiality and is not disclosed without explicit patient consent, except as required by law. Results are reported through secure channels with encrypted transmission.
Clinical & Logistical Metadata
| Test Name | GLB1 Gene Mucopolysaccharidosis Type 4B Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA) – 3–5 mL; also accepts extracted DNA or dried blood spot (FTA card) |
| Methodology Used | Next‑Generation Sequencing (NGS) with orthogonal Sanger confirmation, full gene coverage |
| ICD-10-CM Code | E76.22 (Mucopolysaccharidosis type IVB) |
| LOINC Code | 21615-0 (GLB1 gene mutation analysis) |
| DHA Facility License & Laboratory Address | License No. 1143 · Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE · DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians